These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25446877)

  • 1. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
    Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
    Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?
    Zaborska B; Sikora-Frąc M; Smarż K; Pilichowska-Paszkiet E; Budaj A; Sitkiewicz D; Sygitowicz G
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study.
    Saleh N; Khattab A; Rizk M; Salem S; Abo-Haded H
    BMC Pediatr; 2020 Nov; 20(1):537. PubMed ID: 33248453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis.
    Baccouche BM; Mahmoud MA; Nief C; Patel K; Natterson-Horowitz B
    Curr Cardiol Rev; 2023; 19(3):e171122211004. PubMed ID: 36397629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Testani JM
    J Card Fail; 2024 Feb; 30(2):340-346. PubMed ID: 37301248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Galectin-3 and H-FABP correlate with poor physical performance in patients with congestive heart failure.
    Ahmad F; Karim A; Khan J; Qaisar R
    Exp Biol Med (Maywood); 2023 Mar; 248(6):532-540. PubMed ID: 36803120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is galectin-3 a useful biomarker in stratifying the risk of heart failure in diabetes?
    Cuspidi C; Gherbesi E; Faggiano A
    J Clin Ultrasound; 2023; 51(9):1436-1438. PubMed ID: 37750426
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging biomarkers in heart failure and cardiac cachexia.
    Loncar G; Omersa D; Cvetinovic N; Arandjelovic A; Lainscak M
    Int J Mol Sci; 2014 Dec; 15(12):23878-96. PubMed ID: 25535078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport.
    Goff CL
    Exp Physiol; 2023 Oct; 108(10):1257-1258. PubMed ID: 37638704
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of bioelectrical phase angle in patients with heart failure.
    Scicchitano P; Massari F
    Rev Endocr Metab Disord; 2023 Jun; 24(3):465-477. PubMed ID: 36282462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 as a Biomarker to Predict Cardiorenal Syndrome in Patients with Acute Heart Failure.
    Ozyildirim S; Dogan O; Barman HA; Tanyolaç S; Atıcı A; Enar R; Doğan SM
    Acta Cardiol Sin; 2023 Nov; 39(6):862-870. PubMed ID: 38022413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 and HFpEF: Clarifying an Emerging Relationship.
    Baccouche BM; Rhodenhiser E
    Curr Cardiol Rev; 2023; 19(5):19-26. PubMed ID: 36959138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST2 and Galectin-3: Ready for Prime Time?
    Meijers WC; van der Velde AR; de Boer RA
    EJIFCC; 2016 Aug; 27(3):238-52. PubMed ID: 27683537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.
    Suthahar N; Meijers WC; Silljé HHW; Ho JE; Liu FT; de Boer RA
    Theranostics; 2018; 8(3):593-609. PubMed ID: 29344292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-based Differences in Heart Failure Biomarkers.
    Robles-Mezcua A; Aguado NG; de la Rosa APM; Cruzado-Álvarez C; Rubio CJ; Cabeza AI; Gómez-Doblas JJ; Jiménez-Navarro MF; Pierri MM; García-Pinilla JM
    Curr Heart Fail Rep; 2024 Aug; 21(4):379-388. PubMed ID: 38767760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Inflammasomes in Heart Failure.
    Vlachakis PK; Theofilis P; Kachrimanidis I; Giannakopoulos K; Drakopoulou M; Apostolos A; Kordalis A; Leontsinis I; Tsioufis K; Tousoulis D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?
    Yuen T; Gouda P; Margaryan R; Ezekowitz J
    Curr Heart Fail Rep; 2023 Oct; 20(5):358-373. PubMed ID: 37676613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in Heart Failure Management: A Comprehensive Narrative Review of Emerging Therapies.
    Sapna F; Raveena F; Chandio M; Bai K; Sayyar M; Varrassi G; Khatri M; Kumar S; Mohamad T
    Cureus; 2023 Oct; 15(10):e46486. PubMed ID: 37927716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers for the early detection and management of heart failure.
    Mariappan V; Srinivasan R; Pratheesh R; Jujjuvarapu MR; Pillai AB
    Heart Fail Rev; 2024 Mar; 29(2):331-353. PubMed ID: 37702877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?
    Kirk JA; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1256-H1258. PubMed ID: 29498533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.